NO20061161L - Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel - Google Patents

Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel

Info

Publication number
NO20061161L
NO20061161L NO20061161A NO20061161A NO20061161L NO 20061161 L NO20061161 L NO 20061161L NO 20061161 A NO20061161 A NO 20061161A NO 20061161 A NO20061161 A NO 20061161A NO 20061161 L NO20061161 L NO 20061161L
Authority
NO
Norway
Prior art keywords
rosiglitazone
another anti
new preparation
diabetic agent
dosage form
Prior art date
Application number
NO20061161A
Other languages
English (en)
Norwegian (no)
Inventor
Peter John Coles
Donald Colin Mackenzie
Jr Paul Norman Mudd
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27840010&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061161(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20061161L publication Critical patent/NO20061161L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061161A 2003-08-11 2006-03-10 Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel NO20061161L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318824.0A GB0318824D0 (en) 2003-08-11 2003-08-11 Novel composition
PCT/EP2004/008970 WO2005013956A1 (en) 2003-08-11 2004-08-09 Novel composition comprising rosiglitazone and another antidiabetic agent

Publications (1)

Publication Number Publication Date
NO20061161L true NO20061161L (no) 2006-03-10

Family

ID=27840010

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061161A NO20061161L (no) 2003-08-11 2006-03-10 Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel

Country Status (37)

Country Link
US (1) US20080206336A1 (es)
EP (1) EP1663191B1 (es)
JP (1) JP4714147B2 (es)
KR (1) KR20060071396A (es)
CN (2) CN1835741B (es)
AP (1) AP2006003489A0 (es)
AR (1) AR045230A1 (es)
AT (1) ATE455542T1 (es)
AU (1) AU2004262933B2 (es)
BR (1) BRPI0413419A (es)
CA (1) CA2534480A1 (es)
CY (1) CY1109923T1 (es)
DE (1) DE602004025257D1 (es)
DK (1) DK1663191T3 (es)
EA (2) EA200800966A1 (es)
EC (1) ECSP066338A (es)
ES (1) ES2339554T3 (es)
GB (1) GB0318824D0 (es)
HK (1) HK1092051A1 (es)
HR (1) HRP20100160T1 (es)
IL (1) IL173177A0 (es)
IS (1) IS2745B (es)
MA (1) MA27996A1 (es)
MX (1) MXPA06001629A (es)
MY (1) MY151053A (es)
NO (1) NO20061161L (es)
NZ (1) NZ544632A (es)
OA (1) OA13233A (es)
PE (1) PE20050357A1 (es)
PL (1) PL1663191T3 (es)
PT (1) PT1663191E (es)
SG (1) SG165178A1 (es)
SI (1) SI1663191T1 (es)
TW (1) TW200517146A (es)
UA (1) UA82537C2 (es)
UY (1) UY28461A1 (es)
WO (1) WO2005013956A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
KR20110052641A (ko) * 2008-07-18 2011-05-18 베일언트 파마슈티컬스 인터내셔널 변형 방출형 제형 및 이의 이용 방법
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2011161521A1 (en) * 2010-06-21 2011-12-29 Lupin Limited Compositions comprising metformin and rosiglitazone
MX342120B (es) * 2010-07-09 2016-09-14 William Owen Wilkison Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin.
CN102727459A (zh) * 2011-04-15 2012-10-17 江苏豪森医药集团有限公司 一种具有第一和第二活性药物的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
ATE267589T1 (de) * 1998-04-03 2004-06-15 Egalet As Zusammensetzung mit kontrollierter wirkstoff- freisetzung
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
DE69833179T2 (de) * 1998-11-10 2006-09-07 The Procter & Gamble Company, Cincinnati Bleichmittelzusammensetzungen
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
NZ511614A (en) * 1998-11-12 2003-12-19 Smithkline Beecham P Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EP1231917A2 (en) * 1999-11-16 2002-08-21 Smithkline Beecham Plc Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
AU2001257456B2 (en) * 2000-05-01 2006-02-09 Aeropharm Technology, Inc. A core formulation
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Also Published As

Publication number Publication date
ATE455542T1 (de) 2010-02-15
AU2004262933A1 (en) 2005-02-17
ES2339554T3 (es) 2010-05-21
ECSP066338A (es) 2006-07-28
JP4714147B2 (ja) 2011-06-29
IS2745B (is) 2011-08-15
CN1835741B (zh) 2011-12-14
BRPI0413419A (pt) 2006-10-10
AP2006003489A0 (en) 2006-02-28
HK1092051A1 (en) 2007-02-02
JP2007501830A (ja) 2007-02-01
SI1663191T1 (sl) 2010-05-31
EP1663191A1 (en) 2006-06-07
CN1835741A (zh) 2006-09-20
MY151053A (en) 2014-03-31
AR045230A1 (es) 2005-10-19
CN102397551A (zh) 2012-04-04
CA2534480A1 (en) 2005-02-17
UA82537C2 (uk) 2008-04-25
UY28461A1 (es) 2005-03-31
HRP20100160T1 (hr) 2010-05-31
NZ544632A (en) 2009-03-31
CY1109923T1 (el) 2014-09-10
US20080206336A1 (en) 2008-08-28
GB0318824D0 (en) 2003-09-10
MA27996A1 (fr) 2006-07-03
TW200517146A (en) 2005-06-01
IL173177A0 (en) 2006-06-11
KR20060071396A (ko) 2006-06-26
PL1663191T3 (pl) 2010-06-30
EP1663191B1 (en) 2010-01-20
PE20050357A1 (es) 2005-06-01
DK1663191T3 (da) 2010-04-26
EA200800966A1 (ru) 2009-04-28
IS8337A (is) 2006-03-02
WO2005013956A1 (en) 2005-02-17
OA13233A (en) 2006-12-13
EA011550B1 (ru) 2009-04-28
SG165178A1 (en) 2010-10-28
DE602004025257D1 (de) 2010-03-11
AU2004262933B2 (en) 2009-12-10
PT1663191E (pt) 2010-03-16
EA200600400A1 (ru) 2006-08-25
MXPA06001629A (es) 2006-04-28

Similar Documents

Publication Publication Date Title
NO20061161L (no) Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel
DE60321351D1 (de) Verfahren zur herstellung von oral verzehrbaren darreichungsformen
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
NO20053965L (no) Fremgangsmate for fremstilling av belagt preparat
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
HUP0302553A2 (hu) Egy izotiazol-4-karbonsavamid sói és eljárás az előállításukra és ezek alkalmazására a túlzott mértékű sejtburjánzás visszaszorítására alkalmas gyógyszerkészítmények előállítására
JP2003507435A5 (es)
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
NO20061737L (no) Aminosubstituerte erylamino B2 adrenergiske receptoragonister
MX9200992A (es) Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.
NO20090095L (no) Anvendelse av en hydrofil matriks omfattende et polyakrylsyrederivat, en cellulose-eter og et disintegreringsmiddel for fremstilling av et medikament for behandling av kvinners genitale forstyrrelser
NO20064705L (no) Nye farmasoytiske preparater omfattende agonister av tyroidreseptoren
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
NO20025029L (no) Nye epotilonderivater, fremgangsmÕte for fremstilling derav og deres farmasöytiske anvendelse
DK1674456T3 (da) Nye 1,4-benzothiazepin-1,1-dioxid-derivater med forbedrede egenskaber, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
JP2008513426A5 (es)
AP1736A (en) Oral dosage form for controlled drug release.
NO20014475D0 (no) Fremgangsmåte for behandling av sövn-apnoea
HUP0300777A2 (hu) Tiazolidindion-származék tartarátsója
DK1387837T3 (da) Hidtil ukendte azol- eller triazolderivater, fremgangsmåden til deres fremstilling og deres anvendelse som antimykotiske lægemidler
NZ542305A (en) Treatment of proliferative diseases with an epothilone derivative and radiation
JP2005041866A (ja) 疼痛閾値低下抑制剤
HUP0300770A2 (hu) Tiazolidindion-származék tartarátsója

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application